Kurosawa M, Ogawa E, Sutoh E
Department of Allergy and Respiratory Medicine, Sutoh Hospital, Annaka, Gunma, Japan.
Department of Radiology, Sutoh Hospital, Annaka, Gunma, Japan.
Eur Ann Allergy Clin Immunol. 2019 Sep 16;51(5):213-221. doi: 10.23822/EurAnnACI.1764-1489.94. Epub 2019 Apr 15.
Assessing efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma patients. This study was a 48-week prospective open-label analysis of mepolizumab in 11 asthmatics with chronic rhinosinusitis (CRS). It was administered every 4 weeks. Six patients were aspirin-exacerbated respiratory disease (AERD). Blood eosinophil count was reduced after the first administration, and was continued until 48 weeks. The Sino-Nasal Outcome Test scores, the Lund-MacKay CT scoring, and forced expiratory volume in 1 second were improved. Symptom scores of anosmia and nasal congestion were not improved in the patients with AERD. All oral corticosteroid-dependent patients successfully withdrew from corticosteroids. This pilot study showed mepolizumab improved nasal symptoms and lung function in severe eosinophilic asthma patients with CRS, suggesting efficacy of mepolizumab on the upper and lower airway symptoms in eosinophilic asthma.
评估美泊利珠单抗对重度嗜酸性粒细胞性哮喘患者上、下气道的疗效。本研究是一项对11例患有慢性鼻-鼻窦炎（CRS）的哮喘患者进行的为期48周的美泊利珠单抗前瞻性开放标签分析。每4周给药一次。6例患者为阿司匹林加重的呼吸系统疾病（AERD）。首次给药后血液嗜酸性粒细胞计数降低，并持续至48周。鼻窦结局测试评分、Lund-MacKay CT评分和1秒用力呼气量均有所改善。AERD患者的嗅觉减退和鼻塞症状评分未改善。所有依赖口服糖皮质激素的患者均成功停用了糖皮质激素。这项初步研究表明，美泊利珠单抗可改善患有CRS的重度嗜酸性粒细胞性哮喘患者的鼻部症状和肺功能，提示美泊利珠单抗对嗜酸性粒细胞性哮喘的上、下气道症状有效。
